Stage 3 Melanoma Pathology Report: A Patient Guide
A stage 3 melanoma diagnosis comes with a dense pathology report and a long list of decisions. This article explains Breslow thickness, ulceration, BRAF status, and substages in plain language, and outlines integrative support options studied alongside conventional treatment.
Lung Cancer Biomarkers: What Every New Patient Should Know
A new lung cancer diagnosis triggers biomarker testing, staging scans, and treatment decisions in quick succession. This guide explains what EGFR, ALK, KRAS, and PD-L1 results mean and how integrative care fits alongside your conventional treatment plan.
Neoadjuvant Chemotherapy for Ovarian Cancer: Planning Ahead
If you have just been diagnosed with advanced ovarian cancer, your oncologist may recommend chemotherapy before surgery. This guide explains what neoadjuvant chemotherapy involves, what each cycle looks like, and how to plan integrative support from the very first infusion.
Newly Diagnosed with Hormone-Positive Breast Cancer: Reading Your Pathology Report and Planning Integrative Support
A new HR+ breast cancer diagnosis comes with a pathology report full of numbers and unfamiliar terms. This article explains what ER, PR, HER2, Ki-67, and grade mean in plain language, and reviews the integrative support options with the strongest published evidence.
Newly Diagnosed with Leukemia: Questions to Ask Your Oncology Team and Integrative Care Planning
A leukemia diagnosis can require fast decisions and a rapid intake of unfamiliar information. This guide provides structured questions for your oncology team and an overview of how integrative care planning fits alongside conventional treatment.
Newly Diagnosed With Prostate Cancer: Should You Consider LDN as Part of Your Treatment Plan?
A prostate cancer diagnosis brings many decisions at once. This article reviews what the early evidence says about low-dose naltrexone (LDN) and what newly diagnosed patients should know before talking to their oncologist.
